BofA Upgrades ArQule (ARQL) to Buy
More News related to ARQL
- ArQule, Inc. to Present at Lazard Capital Markets Healthcare Conference
- Beacon Equity Issues Technical Trade Alerts on Market Movers: OPTR, RNWK, ARQL, CROX, WRES, LWSN
- ArQule (ARQL) Tops Q3 Views; Boosts FY08 Outlook
- ArQule Announces Third Quarter Fiscal 2008 Results
- ArQule and Daiichi-Sankyo Enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
More News related to Upgrades
- Merrill Smacks Down the REIT Space: Downgrades 29 Stocks, Upgrades 2
- Roth Capital Upgrades Salesforce.com (CRM) to Buy
- BMO Upgrades Alpha Natural Resources (ANR) to Outperform
- William Blair Upgrades Healthcare Services Group (HCSG) to Outperform
- Roth Capital Upgrades Ariba (ARBA) to Buy
Banc of America upgrades ArQule (Nasdaq: ARQL) from Neutral to Buy.
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics.
Related Categories
UpgradesStocks Mentioned
+0.36Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
